MX385295B - Expresión recombinante de la proteína orf2 de pcv2b en células de insecto. - Google Patents

Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.

Info

Publication number
MX385295B
MX385295B MX2020003626A MX2020003626A MX385295B MX 385295 B MX385295 B MX 385295B MX 2020003626 A MX2020003626 A MX 2020003626A MX 2020003626 A MX2020003626 A MX 2020003626A MX 385295 B MX385295 B MX 385295B
Authority
MX
Mexico
Prior art keywords
insect cells
orf2 protein
recombinant expression
pcv2b orf2
vaccines
Prior art date
Application number
MX2020003626A
Other languages
English (en)
Other versions
MX2020003626A (es
Inventor
Der Heijden - Liefkens Karin Huberdina Antonia Van
Lisette Sanders
Paulus Jacobus Antonius Sondermeijer
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2020003626A publication Critical patent/MX2020003626A/es
Publication of MX385295B publication Critical patent/MX385295B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al campo de vacunas veterinarias, en particular a vacunas porcinas contra PCV2 y enfermedades asociadas. Específicamente, la invención se refiere al hallazgo de que se requiere de una mutación en la proteína ORF2 de PCV2b, para evitar su acumulación nuclear al expresarse en células de insecto; la mutación introduce una Prolina en la posición de aminoácido 131. Esto permite una expresión eficiente en células de insecto, una fácil cosecha y genera grandes cantidades de partículas similares al virus. Las VLP son altamente efectivas en vacunas para porcinos para la reducción de infección por PCV2 o de signos asociados de enfermedad.
MX2020003626A 2017-10-17 2018-10-16 Expresión recombinante de la proteína orf2 de pcv2b en células de insecto. MX385295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17196768 2017-10-17
PCT/EP2018/078189 WO2019076864A1 (en) 2017-10-17 2018-10-16 RECOMBINANT EXPRESSION OF PCV2B ORF2 PROTEIN IN INSECT CELLS

Publications (2)

Publication Number Publication Date
MX2020003626A MX2020003626A (es) 2021-08-12
MX385295B true MX385295B (es) 2025-03-18

Family

ID=60186018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003626A MX385295B (es) 2017-10-17 2018-10-16 Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.

Country Status (13)

Country Link
US (1) US11279952B2 (es)
EP (1) EP3697804B1 (es)
JP (2) JP7062760B2 (es)
KR (1) KR102480771B1 (es)
CN (1) CN111212847B (es)
BR (1) BR112020007498A2 (es)
CA (1) CA3078281C (es)
DK (1) DK3697804T5 (es)
ES (1) ES2962449T3 (es)
HU (1) HUE064720T2 (es)
MX (1) MX385295B (es)
PL (1) PL3697804T3 (es)
WO (1) WO2019076864A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078281C (en) * 2017-10-17 2023-02-21 Intervet International B.V. Recombinant expression of pcv2b orf2 protein in insect cells
CN115960259B (zh) * 2022-10-07 2023-11-24 浙江大学 一种模块化组装双组分纳米颗粒制备方法及其应用
CN115645417A (zh) * 2022-10-17 2023-01-31 武汉轻工大学 鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用
CN117143888B (zh) * 2023-08-29 2024-08-13 上海杰威医药科技有限公司 一种猪圆环病毒2a、2b、2d型三价病毒样颗粒疫苗及其制备方法和应用
CN117965585B (zh) * 2024-03-29 2024-07-16 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 猪圆环病毒2d型佐剂嵌合病毒样颗粒疫苗及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
DK1926496T3 (da) 2005-09-09 2013-09-30 Intervet Int Bv PCV-2-vaccine
GB0712160D0 (en) * 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20100150959A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
TW201043267A (en) 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
WO2014134561A2 (en) * 2013-03-01 2014-09-04 Boehringer Ingelheim Vetmedica, Inc. Quantification of vaccine compositions
KR102319843B1 (ko) * 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US10568954B2 (en) 2014-12-11 2020-02-25 Intervet Inc. Process for ready-to-use PCV/M.Hyo combination vaccine
CN104984335A (zh) * 2015-07-14 2015-10-21 浙江诺倍威生物技术有限公司 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备
HUE068390T2 (hu) 2017-08-03 2024-12-28 Intervet Int Bv 2b genotípusú PCV2 ORF2 proteint tartalmazó vakcina
CA3078281C (en) * 2017-10-17 2023-02-21 Intervet International B.V. Recombinant expression of pcv2b orf2 protein in insect cells

Also Published As

Publication number Publication date
MX2020003626A (es) 2021-08-12
CN111212847B (zh) 2024-01-30
ES2962449T3 (es) 2024-03-19
JP2020537651A (ja) 2020-12-24
HUE064720T2 (hu) 2024-04-28
JP7422795B2 (ja) 2024-01-26
RU2020115868A (ru) 2021-11-18
US20200299726A1 (en) 2020-09-24
KR102480771B1 (ko) 2022-12-23
WO2019076864A1 (en) 2019-04-25
JP7062760B2 (ja) 2022-05-06
DK3697804T3 (da) 2023-11-13
PL3697804T3 (pl) 2024-01-03
CN111212847A (zh) 2020-05-29
EP3697804B1 (en) 2023-08-23
CA3078281A1 (en) 2019-04-25
BR112020007498A2 (pt) 2020-10-06
EP3697804A1 (en) 2020-08-26
DK3697804T5 (da) 2024-08-26
JP2022065059A (ja) 2022-04-26
KR20200066700A (ko) 2020-06-10
RU2020115868A3 (es) 2021-11-18
CA3078281C (en) 2023-02-21
US11279952B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2023009627A (es) Capsides variantes de virus adenoasociados y metodos de uso de las mismas.
MX2020003626A (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
PE20210915A1 (es) Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
MX383330B (es) Particula tipo virus de flavivirus.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
WO2019147867A9 (en) Human antibodies to influenza hemagglutinin
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
MX2019011324A (es) Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
EA202092071A1 (ru) Композиции aav, способы их приготовления и применения
AR111683A1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201991502A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний печени
TH1801000954A (th) วัคซีนสำหรับรักษา hpv18